Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2011 Jan;107(1):28-39.
doi: 10.1111/j.1464-410X.2010.09648.x. Epub 2010 Sep 14.

Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study

Anita V Mitra  1 , Elizabeth K Bancroft, Yolanda Barbachano, Elizabeth C Page, C S Foster, C Jameson, G Mitchell, G J Lindeman, A Stapleton, G Suthers, D G Evans, D Cruger, I Blanco, C Mercer, J Kirk, L Maehle, S Hodgson, L Walker, L Izatt, F Douglas, K Tucker, H Dorkins, V Clowes, A Male, A Donaldson, C Brewer, R Doherty, B Bulman, P J Osther, M Salinas, D Eccles, K Axcrona, I Jobson, B Newcombe, C Cybulski, W S Rubinstein, S Buys, S Townshend, E Friedman, S Domchek, T Ramon Y Cajal, A Spigelman, S H Teo, N Nicolai, N Aaronson, A Ardern-Jones, C Bangma, D Dearnaley, J Eyfjord, A Falconer, H Grönberg, F Hamdy, O Johannsson, V Khoo, Z Kote-Jarai, H Lilja, J Lubinski, J Melia, C Moynihan, S Peock, G Rennert, F Schröder, P Sibley, M Suri, P Wilson, Y J Bignon, S Strom, M Tischkowitz, A Liljegren, D Ilencikova, A Abele, K Kyriacou, C van Asperen, L Kiemeney; IMPACT Study Collaborators; D F Easton, Rosalind A Eeles
Affiliations
Multicenter Study

Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study

Anita V Mitra et al. BJU Int. 2011 Jan.

Abstract

Objective: To evaluate the role of targeted prostate cancer screening in men with BRCA1 or BRCA2 mutations, an international study, IMPACT (Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls), was established. This is the first multicentre screening study targeted at men with a known genetic predisposition to prostate cancer. A preliminary analysis of the data is reported.

Patients and methods: Men aged 40-69 years from families with BRCA1 or BRCA2 mutations were offered annual prostate specific antigen (PSA) testing, and those with PSA > 3 ng/mL, were offered a prostate biopsy. Controls were men age-matched (± 5 years) who were negative for the familial mutation.

Results: In total, 300 men were recruited (205 mutation carriers; 89 BRCA1, 116 BRCA2 and 95 controls) over 33 months. At the baseline screen (year 1), 7.0% (21/300) underwent a prostate biopsy. Prostate cancer was diagnosed in ten individuals, a prevalence of 3.3%. The positive predictive value of PSA screening in this cohort was 47·6% (10/21). One prostate cancer was diagnosed at year 2. Of the 11 prostate cancers diagnosed, nine were in mutation carriers, two in controls, and eight were clinically significant.

Conclusions: The present study shows that the positive predictive value of PSA screening in BRCA mutation carriers is high and that screening detects clinically significant prostate cancer. These results support the rationale for continued screening in such men.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

There are no conflicts of interest to declare.

Figures

FIG. 1
FIG. 1
Identification of Men with a genetic predisposition to ProstAte Cancer: Targeted screening in BRCA1/2 mutation carriers and controls (IMPACT) study design.
FIG. 2
FIG. 2
Year 1 PSA distribution (red line indicates a PSA of 3 ng/mL).
See this image and copyright information in PMC

References

    1. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91:1310–6. - PubMed
    1. Thompson D, Easton DF. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst. 2002;94:1358–65. - PubMed
    1. Schröder FH, Bangma CH. The European Randomized Study of Screening for Prostate Cancer (ERSPC) Br J Urol. 1997;79(Suppl 1):68–71. - PubMed
    1. Prorok PC, Andriole GL, Bresalier RS, et al. Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(Suppl):273–309. - PubMed
    1. Donovan J, Hamdy F, Neal D, et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess. 2003;7:1–88. - PubMed

Substances